tiprankstipranks
Abbott Laboratories (CH:ABT)
:ABT
Switzerland Market

Abbott Laboratories (ABT) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

ABT Analyst Ratings

Strong Buy
16Ratings
Strong Buy
16 Buy
0 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

CHF99.14
▲(12.66% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is CHF99.14 with a high forecast of CHF109.90 and a low forecast of CHF91.18. The average price target represents a 12.66% change from the last price of CHF88.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"66":"CHF66","77":"CHF77","88":"CHF88","99":"CHF99","110":"CHF110"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":109.90084455,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF109.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":99.143354475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF99.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":91.17699696,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF91.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[66,77,88,99,110],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85,86.91544958076923,88.83089916153847,90.74634874230769,92.66179832307692,94.57724790384616,96.49269748461539,98.40814706538461,100.32359664615385,102.23904622692308,104.15449580769231,106.06994538846155,107.98539496923077,{"y":109.90084455,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85,86.08795034423076,87.17590068846154,88.2638510326923,89.35180137692308,90.43975172115384,91.52770206538462,92.61565240961538,93.70360275384616,94.79155309807692,95.8795034423077,96.96745378653846,98.05540413076923,{"y":99.143354475,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85,85.4751536123077,85.95030722461539,86.42546083692308,86.90061444923077,87.37576806153847,87.85092167384616,88.32607528615384,88.80122889846153,89.27638251076922,89.75153612307692,90.22668973538461,90.7018433476923,{"y":91.17699696,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":99.752,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.752,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.752,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.233,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.268,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.268,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.913,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.888,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.469,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.03,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.057,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.011,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF109.90Average Price TargetCHF99.14Lowest Price TargetCHF91.18
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
CHF91.18CHF101.76
Buy
15.64%
Upside
Reiterated
08/14/26
Abbott Laboratories (ABT) Receives a Buy from Citi
Wolfe Research Analyst forecast on CH:ABT
Wolfe Research
Wolfe Research
CHF105.83
Buy
20.26%
Upside
Upgraded
08/13/26
Analysts' Top Healthcare Picks: Liquidia Technologies (LQDA), Abbott Laboratories (ABT)
Bank of America Securities Analyst forecast on CH:ABT
Bank of America Securities
Bank of America Securities
CHF16.28CHF93.62
Buy
6.39%
Upside
Reiterated
08/11/26
Abbott Laboratories (ABT) Receives a Buy from Bank of America Securities
TD Cowen
CHF93.62
Buy
6.39%
Upside
Reiterated
07/28/26
Abbott Laboratories: Buy Rating Backed by Strengthening Nutrition Franchise and 2026 Growth Drivers
UBS
CHF109.9CHF101.76
Buy
15.64%
Upside
Assigned
07/28/26
UBS Issues a Buy Rating on Abbott Laboratories (ABT)
Jefferies Analyst forecast on CH:ABT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF109.9
Buy
24.89%
Upside
Reiterated
07/17/26
Jefferies Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
Piper Sandler Analyst forecast on CH:ABT
Piper Sandler
Piper Sandler
CHF93.62CHF96.06
Buy
9.16%
Upside
Reiterated
07/17/26
Abbott Laboratories (ABT) Receives a Buy from Piper Sandler
Raymond James Analyst forecast on CH:ABT
Raymond James
Raymond James
Buy
Reiterated
07/17/26
Abbott Laboratories (ABT) Gets a Buy from Raymond James
J.P. Morgan Analyst forecast on CH:ABT
J.P. Morgan
J.P. Morgan
CHF89.55CHF97.69
Buy
11.01%
Upside
Reiterated
07/17/26
Abbott price target raised to $120 from $110 at JPMorganAbbott price target raised to $120 from $110 at JPMorgan
Wells Fargo Analyst forecast on CH:ABT
Wells Fargo
Wells Fargo
CHF88.73CHF91.18
Buy
3.61%
Upside
Reiterated
07/17/26
Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), Insmed (INSM)
RBC Capital
CHF105.83
Buy
20.26%
Upside
Reiterated
07/16/26
RBC Capital Sticks to Their Buy Rating for Abbott Laboratories (ABT)
William Blair Analyst forecast on CH:ABT
William Blair
William Blair
Buy
Reiterated
07/16/26
Analysts' Top Healthcare Picks: Alpha Tau Medical Ltd (DRTS), Abbott Laboratories (ABT)
BTIG
CHF106.64CHF109.09
Buy
23.96%
Upside
Reiterated
07/16/26
Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Abbott Laboratories (ABT)
Evercore ISI Analyst forecast on CH:ABT
Evercore ISI
Evercore ISI
CHF97.69CHF91.18
Buy
3.61%
Upside
Reiterated
07/06/26
Abbott price target lowered to $112 from $120 at Evercore ISIAbbott price target lowered to $112 from $120 at Evercore ISI
Robert W. Baird Analyst forecast on CH:ABT
Robert W. Baird
Robert W. Baird
CHF98.5
Buy
11.94%
Upside
Initiated
06/30/26
Abbott initiated with an Outperform at BairdAbbott initiated with an Outperform at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
CHF91.18CHF101.76
Buy
15.64%
Upside
Reiterated
08/14/26
Abbott Laboratories (ABT) Receives a Buy from Citi
Wolfe Research Analyst forecast on CH:ABT
Wolfe Research
Wolfe Research
CHF105.83
Buy
20.26%
Upside
Upgraded
08/13/26
Analysts' Top Healthcare Picks: Liquidia Technologies (LQDA), Abbott Laboratories (ABT)
Bank of America Securities Analyst forecast on CH:ABT
Bank of America Securities
Bank of America Securities
CHF16.28CHF93.62
Buy
6.39%
Upside
Reiterated
08/11/26
Abbott Laboratories (ABT) Receives a Buy from Bank of America Securities
TD Cowen
CHF93.62
Buy
6.39%
Upside
Reiterated
07/28/26
Abbott Laboratories: Buy Rating Backed by Strengthening Nutrition Franchise and 2026 Growth Drivers
UBS
CHF109.9CHF101.76
Buy
15.64%
Upside
Assigned
07/28/26
UBS Issues a Buy Rating on Abbott Laboratories (ABT)
Jefferies Analyst forecast on CH:ABT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF109.9
Buy
24.89%
Upside
Reiterated
07/17/26
Jefferies Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
Piper Sandler Analyst forecast on CH:ABT
Piper Sandler
Piper Sandler
CHF93.62CHF96.06
Buy
9.16%
Upside
Reiterated
07/17/26
Abbott Laboratories (ABT) Receives a Buy from Piper Sandler
Raymond James Analyst forecast on CH:ABT
Raymond James
Raymond James
Buy
Reiterated
07/17/26
Abbott Laboratories (ABT) Gets a Buy from Raymond James
J.P. Morgan Analyst forecast on CH:ABT
J.P. Morgan
J.P. Morgan
CHF89.55CHF97.69
Buy
11.01%
Upside
Reiterated
07/17/26
Abbott price target raised to $120 from $110 at JPMorganAbbott price target raised to $120 from $110 at JPMorgan
Wells Fargo Analyst forecast on CH:ABT
Wells Fargo
Wells Fargo
CHF88.73CHF91.18
Buy
3.61%
Upside
Reiterated
07/17/26
Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), Insmed (INSM)
RBC Capital
CHF105.83
Buy
20.26%
Upside
Reiterated
07/16/26
RBC Capital Sticks to Their Buy Rating for Abbott Laboratories (ABT)
William Blair Analyst forecast on CH:ABT
William Blair
William Blair
Buy
Reiterated
07/16/26
Analysts' Top Healthcare Picks: Alpha Tau Medical Ltd (DRTS), Abbott Laboratories (ABT)
BTIG
CHF106.64CHF109.09
Buy
23.96%
Upside
Reiterated
07/16/26
Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Abbott Laboratories (ABT)
Evercore ISI Analyst forecast on CH:ABT
Evercore ISI
Evercore ISI
CHF97.69CHF91.18
Buy
3.61%
Upside
Reiterated
07/06/26
Abbott price target lowered to $112 from $120 at Evercore ISIAbbott price target lowered to $112 from $120 at Evercore ISI
Robert W. Baird Analyst forecast on CH:ABT
Robert W. Baird
Robert W. Baird
CHF98.5
Buy
11.94%
Upside
Initiated
06/30/26
Abbott initiated with an Outperform at BairdAbbott initiated with an Outperform at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months
Success Rate
16/21 ratings generated profit
76%
Average Return
+3.42%
Copying Matthew Taylor's trades and holding each position for 3 Months would result in 76.19% of your transactions generating a profit, with an average return of +3.42% per trade.
1 Year
Success Rate
17/21 ratings generated profit
81%
Average Return
+12.61%
Copying Matthew Taylor's trades and holding each position for 1 Year would result in 80.95% of your transactions generating a profit, with an average return of +12.61% per trade.
2 Years
Success Rate
16/21 ratings generated profit
76%
Average Return
+31.17%
Copying Matthew Taylor's trades and holding each position for 2 Years would result in 76.19% of your transactions generating a profit, with an average return of +31.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
36
33
38
33
33
Hold
6
6
5
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
39
43
33
33
In the current month, ABT has received 33 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 99.14.
Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is CHF1.15 with a range of CHF1.14 to CHF1.17. The previous quarter’s EPS was CHF1.07. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.
Next quarter’s earnings estimate for ABT is CHF1.15 with a range of CHF1.14 to CHF1.17. The previous quarter’s EPS was CHF1.07. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is CHF10.57B with a range of CHF10.49B to CHF10.71B. The previous quarter’s sales results were CHF10.25B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.
Next quarter’s sales forecast for ABT is CHF10.57B with a range of CHF10.49B to CHF10.71B. The previous quarter’s sales results were CHF10.25B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Stock Forecast FAQ

What is CH:ABT’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 99.14.
    What is CH:ABT’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 12.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbott Laboratories a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy, which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s share price target?
            The average share price target for Abbott Laboratories is 99.14. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF109.90 ,and the lowest forecast is CHF91.18. The average share price target represents 12.66% Increase from the current price of CHF88.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of Abbott Laboratories?
                To buy shares of CH:ABT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.